Progress towards a vaccine against Ebola to meet emergency medical countermeasure needs |
| |
| Institution: | 1. Vaccine and Drug Evaluation Centre, Department of Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada;2. Public Health Ontario, Toronto, ON, Canada;3. Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada;4. Department of Family & Community Medicine, University of Toronto, Toronto, ON, Canada;5. ICES, Toronto, ON, Canada;6. Cumming School of Medicine, University of Calgary, Calgary, AB, Canada;7. Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada;1. Rochester General Hospital Research Institute, Rochester, NY 14621, USA;2. Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, NY 14642, USA;3. Clinical and Translational Research Center, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, The State University of New York, Buffalo, NY 14214, USA;4. Department of Infectious Diseases, College of Veterinary Medicine University of Georgia, Athens, GA 30602, USA;5. Department of Microbiology and Immunology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, The State University of New York, Buffalo, NY 14214, USA;1. College of Physicians and Surgeons, Columbia University Medical Center, 622 W 168th Street, New York, NY 10032, United States;2. Mailman School of Public Health, Columbia University Medical College, 722 W 168th St, New York, NY 10032, United States;3. New York Presbyterian Hospital, 622 W 168th Street, New York, NY 10032, United States;4. Department of Pediatrics, Indiana University School of Medicine, 410 West 10th Street, Suite 1001, Indianapolis, IN 46202, United States;5. Department of Psychology, McGill University, 1205 Dr. Penfield Avenue, Montreal, Quebec H3A 1B1, Canada;6. Department of Behavioral Sciences, Rush University Medical Center, 1645 West Jackson Blvd., Ste. 400, Chicago, IL 60612, United States |
| |
| Abstract: | The Ebola virus epidemic in West Africa proved to be the largest in the history of filovirus outbreaks, causing the World Health Organization to declare a public health emergency of international concern in August of 2014. In collaboration with domestic and international partners, the Biomedical Advanced Research and Development Authority (BARDA) initiated several vaccine development projects in support of the overall response efforts. The urgency associated with the epidemic triggered the clinical evaluation of lead vaccine candidates starting in late 2014. Here we will discuss development of the lead vaccine candidates for Ebola virus, specifically Zaire ebolavirus. |
| |
| Keywords: | Ebola Filovirus Vaccine |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
